Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey. Shapiro Ben David S, Baruch Gez S, Adler L, Kovatch R, et al. Vaccine 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Shapiro Ben David S, Baruch Gez S, Adler L, Kovatch R, et al. Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey. Vaccine 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
PMID: 38281902